Abstract
Several in vitro studies have demonstrated that tumor cells arrested in the G2 and M phases of the cell cycle expressed an increased sensitivity to the tumor necrosis factor (TNF). The scope of the present study was to investigate whether this cycle dependence of TNF effects also exists in vivo. The experiments were performed by using the Lewis lung carcinoma (LLC), which had been allotransplanted to nude mice. In order to induce delays of the tumor cell cycle in G2, the animals were treated with etoposide (40 mg/kg body weight i.p.) or with local radiation (15 Gy), each increasing the G2 fraction of the LLC from 10% to 35% and 50% respectively. For combination therapy with recombinant (r)TNF, the tumor was transplanted to four groups of six mice each, one of them serving as a control group the others being treated either with a G2 inductor alone, with rTNF alone, or with rTNF and a G2 inductor combined. Administration of rTNF (125 or 250 μg/kg body weight i.v.) was always carried out 24 h after therapy with etoposide or radiation when the maximum of G2 accumulation had developed. The growth behavior of the treated tumors revealed that the response of the LLC to rTNF in vivo was not improved by pretreatment with a G2 inductor and, thus, obviously lacked cell-cycle specificity. It is supposed that direct interactions of TNF with the tumor cells, which are a basic requirement for cell-cycle-linked phenomena, play a minor role in the therapeutic outcome of the LLC under in vivo conditions.
Similar content being viewed by others
References
Asher A, Mulé JJ, Reichert CM, Shiloni E, Rosenberg SA (1987) Studies on the anti-tumor efficacy of systemically administered recombinant tumor necrosis factor against several murine tumors in vivo. J Immunol 138: 963
Balkwill FR (1989) Cytokines in cancer therapy Oxford University Press, Oxford, New York, Tokyo
Balkwill FR, Lee A, Aldam G, Moodie E, Thomas JA, Tavernier J, Fiers W (1986) Human tumor xenografts treated with recombinant human tumor necrosis factor alone or in combination with interferons. Cancer Res 46: 3990
Belizario JE, Dinarello CA (1991) Interleukin 1, interleukin 6, tumor necrosis factor, and transforming growth factor β increase cell resistance to tumor necrosis factor cytotoxicity by growth arrest in the G1 phase of the cell cycle. Cancer Res 51: 2379
Budd GT, Green S, Baker LH, Hersh EP, Weick JK, Osborne CK (1991) A Southwest Oncology Group phase II trial of recombinant tumor necrosis factor in metastatic breast cancer. Cancer 68: 1694
Carswell EA, Old LJ, Kassel RL, Green S, Fiore N, Williamson B (1975) An endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci USA 72: 3666
Chapman PB, Lester TJ, Casper ES, Gabrilove JL, Wong GY, Kempin SJ, Gold PJ, Welt S, Warren RS, Starnes HF, Sherwin SA, Old LJ, Oettgen HF (1987) Clinical pharmacology of recombinant human tumor necrosis factor in patients with advanced cancer. J Clin Oncol 5: 1942
Creasey AA, Reynolds MT, Laird W (1986) Cures and partial regression of murine and human tumors by recombinant human tumor necrosis factor. Cancer Res 46: 5687
Darzynkiewicz Z, Williamson B, Carswell EA, Old LJ (1984) Cell cycle-specific effects of tumor necrosis factor. Cancer Res 44: 83
Durbin PW, Jeung N, Kullgren B, Clemons GK (1992) Gross composition and plasma and extracellular water volumes of tissues of a reference mouse. Health Phys 63: 427
Erba E, Ubezio P, Colombo T, Broggini M, Torti L, Vaghi M, D'Incalci M, Morasca L (1983) Flow-cytometric analysis of DNA distribution after VP16-213 treatment of Lewis lung carcinoma. Cancer Chemother Pharmacol 10: 208
Gresser I Belardelli F, Tavernier J, Fiers W, Podo F, Federico M, Carpinelli G, Duvillard P, Prade M, Maury C, Bandu MT, Maunoury MT (1986) Anti-tumor effects of interferon in mice injected with interferon-sensitive and interferon-resistant friend leukemia cells. V. Comparisons with the action of tumor necrosis factor. Int J Cancer 38: 771
Jäckel M, Köpf-Maier P (1991) Influence of cisplatin on cell-cycle progression in xenografted human head and neck carcinomas. Cancer Chemother Pharmacol 27: 464
Kemeny N, Childs B, Larchian W, Rosado K, Kelsen D (1990) A phase II trial of recombinant tumor necrosis factor in patients with advanced colorectal carcinoma. Cancer 66: 659
Malik STA, Griffin DB, Fiers W, Balkwill FR (1989) Paradoxical effects of tumor necrosis factor in experimental ovarian cancer. Int J Cancer 44: 918
Marquardt DW (1963) An algorithm for least-squares estimation of nonlinear parameters. Soc Ind Appl Math 11: 431
Otto F, Göhde W (1976) Effects of fast neutrons and X-ray irradiation on cell kinetics. Pulse Cytophotometry: 244
Palladino MA, Shalaby MR, Kramer SM, Ferraiolo BL, Baughman RA, Deleo AB, Crase D, Marafino B, Aggarwal BB, Figari IS, Liggitt D, Patton JS (1987) Characterization of the antitumor activities of human tumor necrosis factor-α and the comparison with other cytokines: induction of tumor-specific immunity. J Immunol 138: 4023
Watanabe N, Niitsu Y, Yamauchi N, Neda H, Sone H, Maeda M, Urushizaki I (1987) Cell cycle specificity of tumor necrosis factor and its receptor. Cell Biol Int Rep 11: 813
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Jäckel, M., Köpf-Maier, P. & Tausch-Treml, R. Lack of cell-cycle-specific effects of recombinant tumor necrosis factor in vivo. Cancer Immunol Immunother 39, 337–341 (1994). https://doi.org/10.1007/BF01519988
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01519988